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Abstract 
Background 
People who are dependent on opioids have substantially increased risk of premature death, but there 
are few estimates of life expectancy. 
Methods 
We calculated age-specific mortality rates in a cohort of people who had at least one prescription of 
an opioid agonist (methadone or buprenorphine) between 2001 and 2018 in New South Wales, 
Australia. We estimated life expectancy at age 18 based on life tables. We also estimated the potential 
years of life lost before age 75, decomposed by cause of death. 
Results 
The cohort included 47,197 people, with a median of 9.8 years of follow-up. 5,097 participants died, 
and the standardised mortality ratio (compared to the general population of New South Wales) was 
6.06 (95% CI 5.90-6.23). Life expectancy at age 18 was 47.5 years (95% CI 42.9-50.5) for men and 
50.7 years (95% CI 45.4-54.8) for women; deficits of 14.7 and 15.8 years respectively when 
compared to the general population. The largest cause of death was non-communicable physical 
diseases, which accounted for 47% of deaths in life tables for men and 42% for women. Drug-related 
deaths accounted for 16% of deaths for men and 19% for women, but due to the young age at which 
these deaths occur, they contributed approximately one third of potential years of life lost. 
Conclusion 
In common with people with serious mental illnesses, people who are dependent on opioids have 
substantially reduced life expectancy. In both populations most excess deaths relate to non-
communicable physical diseases. 
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Introduction 
People who use opioids such as heroin often use these drugs for many years, which can have a 
profound impact on health and social wellbeing. A large number of cohort studies have measured the 
relative mortality risk associated with opioid dependence. Systematic reviews of such studies have 
found that the risk of death for people who inject drugs (Mathers et al., 2013) and people who 
regularly use heroin and other opioids (Degenhardt et al., 2011) is typically 15 times the general 
population, though this varies widely by setting. These relative risks can be difficult to interpret. In 
particular, the ratio between mortality risk in the general population and the mortality risk for people 
who use illicit drugs tends to be greater for younger samples than for older samples, even if the 
absolute difference is smaller for younger samples. Cause-specific mortality risk can also be difficult 
to interpret. The risk of death due to drug overdoses, suicides, or blood-borne viral infections is many 
times that of the general population, but long-term conditions such as cardiovascular and respiratory 
diseases may cause more deaths despite having lower risk ratios (Lewer et al., 2019). 
Some studies of other marginalised groups, particularly people with serious mental health problems, 
have addressed these issues by estimating life expectancy deficits rather than relative risks (Erlangsen 
et al., 2017; Hjorthøj et al., 2017; Lawrence et al., 2013; Plana-Ripoll et al., 2019). Life expectancy is 
the average age at which people would die if current mortality rates remain unchanged. A systematic 
review of studies into the life expectancy of people with schizophrenia found an average deficit of 15 
years when compared to the general population (Hjorthøj et al., 2017). As a measure of mortality risk, 
life expectancy has the benefits of being (i) independent from the study sample’s age structure, (ii) 
intuitive because it relates to a usual lifespan of around 80 years, and (iii) decomposable by cause of 
death. Despite the large number of studies reporting relative mortality risks for people who use illicit 
drugs, there are few estimates of the life expectancy of this population. 
We aimed to estimate the life expectancy of people who have been prescribed opioid agonist 
treatment in New South Wales, Australia. Opioid agonists are essential medicines prescribed to 
people who are dependent on opioids. They aim to prevent withdrawal, reduce the need to use illicit 
opioids, and reduce health and social harms associated with illicit drugs (Degenhardt et al., 2019). A 
large proportion of people who use illicit opioids have been prescribed opioid agonists either currently 
or historically. We also aimed to calculate the contribution of different causes of death to the years of 
life lost in this population. 
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Methods 
Study population 
We included all patients prescribed an opioid agonist (methadone or buprenorphine) in New South 
Wales between 1 August 2001 and 19 September 2018. The data were drawn from the Opioid Agonist 
Treatment Safety (OATS) Study, a resource of linked electronic healthcare databases that includes all 
authorities to prescribe opioid agonists and probabilistic linkage to mortality information from the 
Cause of Death Unit Record File held by the NSW Ministry of Health Secure Analytics for 
Population Health Research and Intelligence. A detailed description of the OATS Study has been 
published (Larney et al., 2018). 
Individuals entered the cohort at the first treatment after 23 August 2001 (because linked mortality 
information was available from this date), and exit was at the earliest of death, the final date on which 
participants were known to be alive, the participant’s 75th birthday, or 19 September 2018 (the final 
date at which mortality information was available). We excluded patients aged younger than 18 or 
older than 75 at cohort entry. For descriptive purposes, we reported the proportion of patients who 
identified as Aboriginal or Torres Strait Islanders; were in prison prior to study entry; and had 
received a previous diagnosis of schizophrenia (ICD-10 codes F20:29) or bipolar disorder (F31) in 
hospital or specialist mental health services. 
Reference data 
Our reference data were official population estimates and mortality statistics for the general 
population of New South Wales, 2001-2018, from the Australian Bureau of Statistics (Australian 
Bureau of Statistics, 2019).  
Mortality rates and ratios 
We calculated reference mortality rates in the general population by sex, calendar year, and single-
year-of-age from 18 to 74. We then calculated the number of expected deaths by applying these rates 
to the time-at-risk for the study cohort within these strata. We used the Lexis method to calculate 
time-at-risk (Clayton and Hills, 2013). This involved disaggregating follow-up time for each 
participant by day (for example, a participant who joined the cohort on 13 March 2010 and died on 24 
April 2018 would have 2,964 days of observation, with calendar year and age-at-last-birthday 
assigned to each day), and then summarising the number of days of observation by sex, calendar year, 
and single-year-of age. We calculated the standardised mortality ratio (SMR) as the observed deaths 
divided by the expected deaths. 
Life expectancy at age 18 
We estimated life expectancy for men and women using the life table method described by the UK 
Office for National Statistics (Office for National Statistics, 2018). For ages 25 to 64, we used 
mortality rates from the OATS cohort. There was limited follow-up time outside of this age range so 
mortality rates were imprecise, and we therefore used scenarios. Mortality rates increased 
exponentially between ages 24 and 64 (Fig 1.), and we used Poisson models to predict the mortality 
rate at ages 18-24 and 65-99, separately for men and women. These models suggested that mortality 
rates increased by 6.2% per year for men and 6.4% per year for women. The ‘base’ scenario was the 
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maximum of this predicted rate and the general population rate (as these rates converged at age 86 for 
men and 89 for women). The ‘low’ scenario was the mortality rate in the general population. The 
‘high’ scenario for ages 18-24 was three times the predicted mortality rate; and the ‘high’ scenario for 
ages 64-99 was the SMR for ages 18-74 multiplied by the rate in the general population 
(unrealistically high, because the SMR reduced with age). Mortality of 100% was forced at age 100. 
We estimated uncertainty using a Monte-Carlo method with 10,000 simulations. Simulations for ages 
25-64 were sampled from a Poisson distribution with a mean of the observed number of deaths. 
Simulations for ages 18-24 and 65-99 were sampled from uniformly spaced trajectories between the 
‘low’ and ‘high’ scenarios. We calculated life expectancy in each scenario and reported the 2.5% and 
97.5% quantiles. For comparison, we also calculated life expectancy in the general population.  
We did three sensitivity analyses: (1) with mortality rates based on follow-up truncated at 5, 10 and 
15 years; (2) excluding all participants with an episode of opioid agonist treatment before 1 January 
2001 (i.e. excluding prevalent cases); and (3) stratifying results by period. Sensitivity analyses 1 and 2 
are designed to test whether mortality deficits reduce after longer periods of follow-up (as participants 
stop using drugs), in which case we expected to see shorter life expectancies under these scenarios. 
Full results of these analyses are provided in Supplementary Information. 
Cause-specific potential years of life lost 
We used life tables to estimate the potential years of life lost before age 75, assuming that deaths at 
age 74 lose 0.5 years; deaths at age 73 lose 1.5 years, etc. For this analysis, we used cause-specific 
mortality rates in the cohort at each age from 18-74 rather than using scenarios for younger and older 
age ranges. Causes of death were grouped according to the underlying cause of death into ‘drug-
related’ (ICD-10 codes F11-16, F19, F55, X40-X44, and Y10-Y14), non-communicable physical 
diseases (ICD-10 chapters II: cancers, III: blood, IV: endocrine/nutritional/metabolic diseases, VI: 
nervous system, VII: eye, VIII: ear, IX: circulatory, X: respiratory, XI: digestive, XII: skin, XIII: 
musculoskeletal, and XIV: genitourinary), infections (ICD-10 chapter I: infections), mental health and 
suicide (ICD-10 codes F00-F10, F20-F99, X60-X84), accidents and homicide (ICD-10 chapters XIX: 
injuring and poisoning excluding drug-related deaths, and XX: external), and all other causes. Some 
deaths, particularly those occurring in 2017 and 2018, did not yet have a recorded cause. In these 
cases we classified the cause as ‘to be confirmed’. We divided the total years-of-life lost in each life 
table by 100,000 to estimate the average years lost per-person. 
All analysis was conducted using R version 3.6.0. We have posted code and data that replicate the 
main results at https://github.com/danlewer/oats. 
Ethics and approvals 
This study is approved by the NSW Population and Health Services Research Ethics Committee 
(2018/HRE0205) and Aboriginal Health and Medical Research Council Research Ethics Committee 
(1400/18). 
Role of the funding source 
The funder had no role in the study design; in the collection, analysis, and interpretation of data; in the 
writing of the report; or in the decision to submit the paper for publication. 
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Results 
The cohort included 47,197 participants, of which 32,048 (68%) were male and the median age at 
cohort entry was 32.8 (IQR 26.6-40.4). Table 1 provides descriptive information. A large proportion 
of participants entered the cohort in 2001-2006 as individuals with previous opioid agonist 
prescriptions joined the study at the start of follow-up (i.e. prevalent cases). Participants had a median 
of 9.8 years (range 0-17.1, IQR 3.7-15.4) of follow-up and 5,097 (11%) died. The median age of 
death was 47.1 (IQR 38.1-54.1). 
<< Table 1: characteristics of people at first prescription of opioid agonist treatment in New South 
Wales, Australia, between 2001 and 2018 >> 
Mortality rates and ratios 
Mortality rates increased exponentially with age (Fig. 1). Men had higher crude mortality rates than 
women at all ages (table 2). For the whole cohort, the SMR was 6.06 (95% CI 5.90-6.23), and SMRs 
reduced with age. 
<< Fig. 1: mortality rates in a cohort of people prescribed opioid agonists in New South Wales, 
2001-2018, by age and sex >> 
<< Table 2: Standardised mortality ratios by age and sex >> 
Life expectancy at age 18 
Life expectancy at age 18 was 47.5 years (95% CI 42.9-50.5) for men with a history of opioid 
dependence, compared to 62.2 for men in the general population, so the gap in life expectancy was 
14.7 years. Life expectancy at age 18 for women with a history of opioid dependence was 50.7 years 
(95% CI 45.4-54.7), compared to 66.5 for the general population, so the gap in life expectancy was 
15.8 years. These values represent years of life expected after age 18 (rather than the average age of 
death). In sensitivity analyses with truncated follow-up, estimates of life expectancy were between 0.2 
years younger and 2.2 years older (with the shortest follow-up having the oldest life expectancy) and 
in analyses of incident cases only estimates were 2.7 years older for men and 3.5 years older for 
women (full results of the sensitivity analysis are shown in Supplementary Information 5). 
Causes of death and potential years of life lost 
Before weighting deaths by age, non-communicable physical diseases caused 42% of deaths for both 
men and women before age 75 in life-table analysis, while drug overdoses caused 18% and 19% of 
deaths for men and women respectively. Because drug overdoses occurred at a younger age (mean 
age of death 40.4 for men, compared to 60.8 for non-communicable diseases), each death contributed 
more potential years of life lost. After weighting deaths by age, non-communicable physical diseases 
and drug-related deaths each contributing approximately one-third of years of life lost. Fig. 2 shows 
the transition from drug-related causes to non-communicable diseases over the life course, and 
number of deaths by cause are shown in Supplementary Information 6.  
<< Fig 2: Cumulative years-of-life lost and deaths, by cause of death >> 
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Discussion 
People who are dependent on opioids have substantially raised risk of death. Our results show that life 
expectancy in people with opioid use disorders this population is approximately 15 years shorter than 
the general population; similar to studies of life expectancy among people with serious mental 
illnesses (Hjorthøj et al., 2017; Lawrence et al., 2013). These large health inequalities are related to 
multiple causes of death, with drug-related deaths contributing most at younger ages and non-
communicable physical diseases at older ages. 
Although mortality rates among people who use drugs are extremely high, these results show that a 
large proportion of people who experience these mortality rates throughout life will survive to an age 
where non-communicable diseases become the main cause of death and morbidity. The health needs 
of people in their 50s, 60s and 70s who use opioids (or used to use opioids) are likely to relate 
primarily to non-communicable diseases, rather than infections or drug-related problems. 
Relation to other studies 
The life expectancy deficit for people who are dependent on opioids far exceeds that associated with 
socioeconomic status alone. Life expectancy at birth in the general population of New South Wales 
was 83.6 in 2017, and was 2.3 years younger for people living in the most deprived quintile of 
neighbourhoods, and 2.5 years older for people living the least deprived quintile (“HealthStats NSW: 
Life expectancy,” 2019). The high mortality rate among people who use opioids is a result of multiple 
risk factors, including opioid overdose; chronic toxicity of drugs such as the cardiotoxic effect of 
methamphetamine (Kaye and McKetin, 2005), which is commonly used in addition to opioids; 
tobacco smoking, which is nearly universal (Pajusco et al., 2012); hepatitis viral infections and 
alcohol use, which have a synergistic effect on the risk of cirrhosis and liver cancer (Corrao and 
Aricò, 1998); poor nutrition; and the high prevalence of mental health problems that increase the risk 
of suicide (Poorolajal et al., 2016). 
We are aware of two prior studies of life expectancy among people who use opioids. One was small, 
including 106 deaths, finding life expectancy deficits of 9.0 years for men and 17.3 years for women 
(Hayes et al., 2011). The other included 1,005 deaths and focused on people starting methadone 
treatment in Spain in the 1990s (Brugal et al., 2005). Half of participants were HIV-positive; much  
higher than in contemporary samples of people who use opioids in high income countries, including 
Australia (Degenhardt et al., 2017), and life expectancy in this study was 38 years lower than the 
general population. Our study has the advantage of size (with 5,097 deaths), long follow-up, and 
inclusion of the whole population of people prescribed opioid agonists. 
There are further studies of life expectancy in other socially excluded groups that often overlap with 
people who are dependent on opioids. Most studies focus on people with a diagnosis of a serious 
mental health problem, and a small number of studies focus on people with a history of any substance 
use disorder (including alcohol), homelessness, or prison. All of these studies found similarly large 
deficits in life expectancy compared to the general population. For example, a study of 32,711 people 
with experience of homelessness in Denmark estimated deficits of 22 years for men and 17 years for 
women (Nielsen et al., 2011). Where these studies decomposed deaths by disease, non-communicable 
diseases were the main cause of death, in common with our results. A review of studies of life 
expectancy in populations experiencing social exclusion is given in Supplementary Information. 
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Limitations 
There are four main limitations to the study. First, the period life expectancy method assumed that 
mortality rates observed in our study are experienced throughout life. Actual mortality rates may 
differ because: (i) many individuals start using opioids later than age 18. The typical age of initiation 
varies by setting and period, but is usually between the late teens and mid-20s (Brecht et al., 2007; 
Hser et al., 2001); (ii) there is often a gap between initiation of drug use and the start of opioid agonist 
treatment, which is associated with higher mortality risk as people do not have the protective effect of 
opioid agonists (Sordo et al., 2017). The median age when participants in our study had a first episode 
of opioid agonist treatment was 30.4 (Supplementary Information 3), which is likely to be older than 
the age when people first used illicit opioids; and (iii) the episodic nature of drug use and potential 
cessation. Some members of the cohort may ‘recover’ after the end of follow-up, meaning that the life 
expectancy deficits in our study are overstated. Our study had relatively long follow-up (median 10 
years) and episodic drug use is therefore partially reflected in our data. Cohort studies with very long 
follow-up (Oppenheimer et al., 1994; Smyth et al., 2007) show that opioid use and high mortality 
rates persist for decades, and some consider opioid dependence to be a chronic condition (Kleber, 
2008). Also, the large proportion of deaths that relate to non-communicable diseases, rather than the 
acute effects of drugs, suggests that mortality rates are unlikely to fully recover even at complete 
cessation of drug use. Our sensitivity analyses did not suggest that life expectancy was shorter with 
truncated follow-up – in fact there was some evidence that life expectancy was longer in these 
sensitivity analyses, suggesting that mortality deficits may worsen rather than recover over time. 
These limitations are common to studies of life expectancy among marginalised groups, which also 
estimate period life expectancy and do not account for mortality rates prior to diagnosis or ‘recovery’. 
Second, our study excluded individuals who are dependent on opioids but have never accessed opioid 
agonist therapy. This is likely to be a minority in Australia. In a community-recruited sample of 
people who inject drugs in Melbourne, for example, only one in four had never been prescribed an 
opioid agonist, and this study explicitly aimed to recruit people with limited contact with drug 
treatment services (Horyniak et al., 2013). This population may have higher mortality risk because 
they do not have the protective effect of opioid agonists, or lower risk because they have less severe 
opioid dependence and therefore lower need for opioid agonists. 
Third, mortality rates and causes of death in this population are affected by drug markets, which 
change over time and geographies, limiting the generalisability of our findings. For example, illicitly 
manufactured fentanyl (which is many times more potent than heroin) has recently become more 
common in North America. This has been associated with increasing numbers of drug overdoses 
(Slavova et al., 2017) and may be associated with reductions in life expectancy and an increasing 
proportion of deaths due to drug overdoses in this population. During the time period covered in this 
study, fentanyl has not yet been found in illicit opiates in Australia. 
Fourth, we did not have data on deaths outside of New South Wales. This is likely to mean that 
mortality rates are underestimated, and hence life expectancies overestimated. However, we do not 
think this is a major bias because the sensitivity analyses with truncated follow-up do not show 
shorter life expectancies. If a substantial number deaths occurred outside of New South Wales, this 
would likely have a greater impact on analyses with longer follow-up. 
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Conclusion 
In common with people with serious mental illnesses, people who are dependent on opioids have 
substantially reduced life expectancy. In both populations, most deaths relate to non-communicable 
physical diseases. 
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Tables 
Table 1: characteristics of people in opioid agonist treatment in New South Wales, Australia, between 




Total  47,197 (100.0) 
Age at cohort entry 18-24  8,828 (19.0) 
 
25-34 18,506 (39.0) 
 
35-44 13,611 (29.0) 
 
45-54  5,327 (11.0) 
 
55-64    839 (2.0) 
 
65-74     86 (<0.1) 
 
Median (IQR) 32.8 (26.6-40.4) 
Sex Male 32,048 (68.0) 
 
Female 15,149 (32.0) 
Year of cohort entry 2001-2006 28,473 (60.0) 
 
2007-2012  9,804 (21.0) 
 
2013-2018  8,920 (19.0) 
Aboriginal and/or Torres Strait Islander 
 
9,859 (21.0) 
Previous incarceration  13,297 (28.0) 
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rate / 10,000 person 
years (95% CI) 
Expected 
deaths SMR (95% CI) 
Male 18-24 15,160 86 567 10.1 8.50 (6.72-10.38) 
 25-34 98,255 554 564 78.5 7.06 (6.49-7.65) 
 35-44 124,824 978 784 160.1 6.11 (5.73-6.49) 
 45-54 84,097 1,206 1,434 231.7 5.20 (4.91-5.50) 
 55-64 27,139 762 2,808 160.5 4.75 (4.41-5.09) 
 65-74 2,171 92 4,238 27.2 3.38 (2.72-4.08) 
 Total 351,646 3,678 1,046 668.1 5.51 (5.33-5.68) 
Female 18-24 10,093 30 297 2.5 12.00 (8.00-16.40) 
 25-34 52,121 225 432 17.7 12.72 (11.08-14.42) 
 35-44 62,184 392 630 43.1 9.09 (8.21-9.99) 
 45-54 40,198 507 1,261 65.8 7.71 (7.04-8.38) 
 55-64 11,483 239 2,081 37.9 6.31 (5.52-7.13) 
 65-74 779 26 3,338 5.7 4.53 (2.79-6.28) 
 Total 176,858 1,419 802 172.7 8.22 (7.79-8.65) 
Total 18-24 25,253 116 459 12.6 9.19 (7.53-10.86) 
 25-34 150,377 779 518 96.2 8.10 (7.54-8.67) 
 35-44 187,008 1,370 733 203.3 6.74 (6.39-7.10) 
 45-54 124,295 1,713 1,378 297.5 5.76 (5.49-6.03) 
 55-64 38,622 1,001 2,592 198.3 5.05 (4.74-5.36) 
 65-74 2,950 118 4,000 32.9 3.58 (2.94-4.25) 
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1 Existing studies of life expectancy in marginalised 
populations 
Studies of relative mortality risk 
A large number of studies have measured mortality among marginalised populations and reported the 
relative mortality risk (typically using standardised mortality ratios). These are summarised in table S1. 
These reviews suggest large literatures on the mortality of people who use opiates and alcohol and 
people with serious mental health problems. There is less research into mortality among people who 
use other drugs (including cocaine and amphetamines), people who have experience of 
homelessness, prison, or sex work. 
Studies consistently show higher mortality rates among older participants, men, and (for people who 
use opiates) those who are not in opioid substitution therapy. 






Pooled CMR / 1,000 
person-years Pooled SMR 
Mathers 2013[1] People who inject drugs 76 23.5  
(21.2 to 25.8) 
14.68  
(13.01 to 16.35) 
Degenhardt 
2011[2] 
Regular or dependent users of 
opioids 
58 20.9  
(19.3 to 22.6) 
14.66  
(12.82 to 16.50) 
Roerecke 2013[3] Alcohol use disorder 81 - Men: 3.38  
(2.98 to 3.84); 
Women: 4.57 
(3.38 to 5.42) 
Sordo 2017[4] People with opioid 
dependence, comparing 
periods in and out of opioid 
substitution therapy 
19 11.3 in MMT;  
36.1 out of MMT;  
4.3 in BMT; 




Dependent cocaine users 7 5.3 to 61.1 4-8 
Singleton 2009[6] Amphetamine users 7 0 to 29.5 6.22 (from one 
study only) 
Hayes 2015[7] Bipolar affective disorder 31 - 2.05  
(1.89 to 2.23) 
Walker 2015[8] People with mental health 
disorders 
203 - 2.22  
(2.12 to 2.33) 
Saha 2007[9] People with schizophrenia 37 - 2.50  
(2.18 to 2.43) 
Zlodre 2012[10] Released prisoners 18 7.2 to 20.5 Men: 1.0 to 9.4; 
Women: 2.6 to 
41.3 
Aldridge 2018[11] Homeless people, prisoners, 
sex workers, people with 





- Men: 7.88  
(7.03 to 8.74); 
Women: 11.86 
(10.42 to 13.30) 
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Studies of life expectancy 
Methods 
We reviewed literature on life expectancy or the life expectancy gap for marginalised groups. We 
defined the ‘life expectancy gap’ as the difference between life expectancy for the study group and the 
general population. Following previous research,[12] marginalised groups were defined as people 
with experience of serious mental illness, substance use disorders or illicit drug dependence, 
homelessness, imprisonment, or sex work. 
We searched Medline and Google Scholar from inception to 17 February 2020 for ‘life expectancy" 
AND (‘substance misuse" OR ‘substance abuse" OR ‘substance use" OR ‘drug dependen*" OR ‘illicit 
drug*" OR heroin OR ‘crack cocaine" OR methamphetamine OR (inject* adj2 drug*) OR methadone 
OR buprenorphine OR \serious mental" OR \severe mental" OR schizophrenia OR bipolar OR 
psychosis OR homeless* OR \sex work" OR *prison* OR incarcerat*). 
Studies 
Our search yielded 563 results, of which 45 were relevant after screening titles and abstracts. After 
full-text review, 33 studies included estimates of life expectancy or a life expectancy gap. Some of 
these studies included estimates for more than one population. Where studies included data points for 
multiple mental health disorders, we extracted a data point for schizophrenia. We extracted a total of 
38 data points. 
Evidence was mostly from Scandinavia and North America. Out of 38 data points, 16 were from 
Scandinavia, 9 from North America, 6 from the UK (all using the same dataset), 2 from Australia, and 
1 from each of Spain, the Netherlands, Hungary and Ethiopia. 23/38 data points related to mental 
health problems, of which 12/23 have been synthesised in a previous systematic review of life 
expectancy among people with schizophrenia, which found a pooled life expectancy gap of 14.5 years 
(95% CI 11.2-17.8).[13] The remaining 11/23 studies focused on people with severe rather than 
common mental health problems (such as bipolar disorder or major depressive disorder, rather than 
mild or moderate depression), mainly because samples were drawn from registers of people with 
mental health diagnoses. 11/38 data points were for people with substance use disorders. 4/11 were 
of people living with HIV who have a history of injecting drugs;[14–17] 5/11 were for people who use 
any substances including alcohol;[18–22] and the remaining 2/11 focus on people who use opiates. 
One is a small sample from London, UK, with only 106 deaths during follow-up.[19] The other 
included 1,005 deaths, and is of people starting methadone treatment in Spain between 1992 and 
1999.[23] 2/38 studies looked at homeless populations; 2/38 at people with experience of prison; and 
0/38 on people with experience of sex work. 
The average age of participants at study baseline ranged from 29.3[23] to 50.1.[24] Younger study 
samples (with an average age under 35) were from studies of people with experience of drugs or 
prison, and one study of people with schizophrenia in Taiwan. Older samples (with an average age 
over 45) were from studies of people with mental health problems (apart from one study of people 
living with HIV who have a history of injecting drugs). An average of 29% of samples of people with 
substance use disorders were female, compared to 50% for sample of people with mental health 
disorders. 
Methodologies 
All studies estimated period life expectancy by calculating age-specific mortality rates from a cohort 
study and using these rates in life tables. No studies estimated a cohort life expectancy (i.e. the 
expected average of death of a specific cohort of marginalised people, making assumptions about 
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future mortality rates in that cohort, or following an entire cohort until all have died). Most studies used 
the abridged life table method that uses mortality rates in age bands rather than by single-year-of-
age.[25] Cohorts usually had few participants at older ages and assumptions about mortality rates at 
older ages were sometimes broad or unclear, such as using mortality rates for participants aged 55+ 
for all ages until death (when most deaths in the study are at the younger end of this age band). 
Some studies estimated mortality rate ratios using standardisation or regression models, then applied 
these ratios to general population life tables.[26–29] The abridged life table method and the approach 
using ratios are designed to smooth out rates or deal with age strata with zero deaths. Most studies 
estimated life expectancy at a certain age (for example 15 or 20), while those that estimated life 
expectancy at birth used mortality rates of the general population until an assumed minimum age of 
onset or diagnosis.[18,20,23,26,27,30–32] Two studies of people with mental health problems 
accounted for differing age at onset, arguing that calculating life expectancy from a minimum age of 
onset can overstate the average life expectancy gap.[22,33] This approach therefore aims to estimate 
the burden of mental illness across a population, rather than for people at a specific age. 
All studies of people with substance use disorders or mental health problems except two[27,31] were 
based on cohorts of people with certain diagnoses (such as `schizophrenia' or `alcohol dependence') 
made in healthcare settings, and therefore do not account for survival prior to diagnosis. Studies 
included a mixture of incident and prevalent cases. The two exceptions recruited people with 
prevalent mental health problems using community surveys and then followed them up. Studies of 
people with experience of homelessness and prison were based on samples from relevant services. 
Life expectancy results 
All studies found large life expectancy gaps. Among the studies of life expectancy of people with 
substance use disorders, life expectancy gaps were very large among people living with HIV with a 
history of drug injection, with gaps of around 30 years. The study of people starting methadone 
treatment in Spain in the 1990s also had a very large life expectancy gap (38 years), which may reect 
the fact that 51% of the sample were HIV positive and 59% reported injecting. More recent studies of 
people with substance use disorders found life expectancy gaps ranging from 9.0 to 23.6 years for 
men and 13.4 to 22.6 years for women. Where studies reported the life expectancy gap separately for 
people with serious mental health problems and people with substance use disorders, those with 
substance use disorders had larger gaps.[18,20–22,34] 
Causes of death 
Almost all studies that decomposed the life expectancy gap by cause of death found that the majority 
of the gap was attributable to ‘natural’ causes or non-communicable diseases.[18,22,26,32,33,35–40] 
For example, a large study in Western Australia found that “almost 80% of excess deaths in people 
with mental illness are due to physical health conditions.”[20] While relative risks are highest for 
‘external’ causes of death such as suicide, trauma, homicide and drug overdose, the most deaths in 
these studies were caused by common non-communicable diseases such as cancers, cardiovascular, 
and respiratory diseases. The exceptions were a study in rural Ethiopia where over half of deaths 
among people with serious mental illnesses were due to infectious diseases,[31] and the study of 
people entering methadone treatment in Spain in the 1990s, where 38% of deaths were due to 
AIDS.[23] 
Mortality rates 
Where studies reported mortality rates and rate ratios (comparing the study population to the general 
population) by age, rates increased with age and rate ratios decreased.[19,30,41–43] Detailed results 
from four studies suggested that mortality rates may plateau or even decrease in marginalised 
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populations up to age 30, and then increase,[22,34,39,42] though the robustness of this observation 
or possible reasons are unclear. 
Conclusion 
Although marginalised populations differ widely in terms of their demographics and social risk factors, 
all have substantially reduced life expectancy, with the gap mainly relating to common non-
communicable diseases. 
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Table S2: Studies of life expectancy in marginalised populations 





































53,237 1,446 17% 45.3 30 29.4 31.9  45 50.7  15.6 18.8  
Schizophrenia 13,823 296 45% 48.9 30 37.1 41.2  45 50.7  7.9 9.5  
Brugal 2005[23] 








5,047 1,005 23% 29.3 0   39   77   38 
Lloyd-Smith 
2006[16] 




















Europe & US 













10,922 348 30% 
43.5 













0 68.4 64.3  77.4 81.6  9 17.3  
Dependent on 
alcohol 







Denmark 48,764 7,497 - - 15 57.8 64.6  76.5 80.9  18.7 16.3  
                                                     
a Presented in some studies as a mean and in others as a median. Where the study only presents age categories, we estimated a mean age using the mid-point of categories (i.e. linear 
interpolation) 
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Men Women Both Men Women Both Men Women Both 
Nielsen 2011[42] Homeless 
1999-
2009 











































105,463 14,971 50% - 15 40.9-50.3 48.8-55.0     12.7-20.0 11.0-16.9  
Lawrence 
2013[20] 






12,163 973 34% - 0 57.4 63.1  79.1 83.8  21.7 20.7  









39,393 2,915 - - 15       21.3-23.6 17.6-22.6  
Schizophrenia 
spectrum 












prison to parole 
1989-
2003 
















Denmark 22,635 - 60% 46.2 15 48.6 55.2  60.7 64.1  12.1 8.9  
                                                     
b Not provided in published article - we took general population values for 2012 from the World Bank (https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=ET) 
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- - - - 1 65.5 72.6  77.7 82.8  12.2 10.2  
Patterson 
2015[15] 























Denmark 78,516 - 63% - 15 46.1 54.5  60.1 64.6  14 10.1  
Leng 2016[28] Schizophrenia 
2000-
2011 










US 11,563 2,013 63% 49.5 0 63.6 65.6  70.2 73  6.6 7.4  
Bitter 2017[24] Schizophrenia 
2006-
2013 
















19,106 1,558 - - 0 67.9 72.2  78.5 82.4  10.6 10.2  
Althoff 2019[14] 













154,335 55,844 - - Diagnosis       14.8 13.4  
Schizophrenia 103,848 32,357 - - Diagnosis       12.1 9.4  
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2 Histograms of age at cohort entry 
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3 Survival curves 
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4 Sensitivity analysis with truncated follow-up 
Table S3: Results of sensitivity analysis, with truncated follow-up or restricted to incident 
cases 
Sex Scenario Life expectancy at age 18 Difference from main 
analysis 
Male Main analysis (complete follow-up) 47.52 (42.89-50.52) - 
 Follow-up truncated at 15 years 47.32 (42.77-50.37) -0.20 
 Follow-up truncated at 10 years 47.74 (42.39-50.46) +0.22 
 Follow-up truncated at 5 years 48.33 (42.11-50.50) +0.81 
 Incident cases only 50.22 (43.35-51.95) +2.70 
Female Main analysis (complete follow-up) 50.71 (45.44-54.74) - 
 Follow-up truncated at 15 years 50.57 (45.28-54.70) -0.14 
 Follow-up truncated at 10 years 51.56 (45.44-55.26) +0.85 
 Follow-up truncated at 5 years 52.87 (45.55-56.25) +2.16 
 Incident cases only 54.24 (46.43-56.90) +3.52 
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5 Causes of death before age 75 





Mean age at 
death 
Number of 
deaths in a 
life table of 
100,000 (%) 
Mean age at 
death in life 
table 
analysis 
Years of life lost 
per person in life 
table analysis (%) 
Male Drug-related 1,057 (29%) 40.39 11,750 (16%) 40.0 4.2 (30%) 
 Non-communicable diseases 1,174 (32%) 51.13 34,012 (47%) 61.5 4.2 (30%) 
 Accidents 218 (6%) 40.47 2,497 (3%) 40.1 0.9 (6%) 
 Infections 287 (8%) 50.36 4,234 (6%) 55.3 0.9 (6%) 
 Mental health and suicide 302 (8%) 40.93 3,917 (5%) 39.8 1.4 (10%) 
 Other 58 (2%) 44.34 1,099 (2%) 56.1 0.2 (2%) 
 TBC 582 (16%) 49.91 15,337 (21%) 61.4 2.2 (16%) 
 Total 3,678 (100%) 46.21 72,846 (100%) 55.2 14.1 (100%) 
Female Drug-related 414 (29%) 41.12 10,706 (19%) 45.6 3.3 (29%) 
 Non-communicable diseases 500 (35%) 48.70 23,350 (42%) 59.4 3.9 (35%) 
 Accidents 83 (6%) 39.31 2,259 (4%) 47.1 0.7 (6%) 
 Infections 86 (6%) 49.56 4,004 (7%) 59.5 0.7 (6%) 
 Mental health and suicide 95 (7%) 40.27 1,867 (3%) 41.4 0.6 (6%) 
 Other 19 (1%) 44.92 830 (1%) 54.7 0.2 (2%) 
 TBC 222 (16%) 49.51 13,104 (23%) 61.3 1.9 (17%) 
 Total 1,419 (100%) 45.50 56,121 (100%) 56.0 11.2 (100%) 
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6 Results stratified by time period 
We stratified results into three periods: 2001-2006, 2007-2012, and 2013-2018. For each period, we 
calculated age-specific mortality rates in the study cohort using the ‘Lexis’ method described in the 
article. This means that the duration of follow-up and the number of deaths were calculated daily for 
individuals under observation during each period. We then repeated the procedures described in the 
article for each period. 
The results are shown in table S5. The age of participants increases during the study. This may be 
primarily a period effect in which people join the cohort at successively older ages, rather than an age 
effect in which individuals in the cohort age during follow-up (evidenced by the increase in the mean 
age of incident cases). 
The crude mortality rates increase for both men and women, which is expected given the increase in 
mean age. There is no clear evidence of life expectancy of the study population increasing or 
decreasing during the study. 
Table S5: Results stratified by period 
Sex Value 2001-2006 2007-2012 2013-2018 All years 
Male Person-years 73,954 128,426 149,266 351,646 
 Mean age (sd) 36.3 (8.8) 39.6 (9.3) 43.3 (9.8) 40.5 (9.8) 
 Mean age: incident (sd) 29.8 (8.3) 32.6 (9.2) 35.0 (10.0) 32.4 (9.4) 
 Number of deaths 588 1298 1792 3678 
 CMR/100,000 pys 795 1011 1201 1,046 
 LE 18: OATS 47.93 (41.40-49.97) 46.40 (42.55-49.97) 47.80 (43.43-51.23) 47.52 (42.89-50.52) 
 LE 18: Gen. Pop. 60.87 62.33 63.21 62.21 
 Deficit 12.93 15.93 15.41 14.69 
Female Person-years 39,235 63,959 73,664 176,858 
 Mean age (follow-up) 35.1 (8.7) 38.7 (9.2) 42.8 (9.7) 39.6 (9.8) 
 Mean age: incident 28.5 (8.3) 32.1 (9.1) 35.7 (10.6) 31.9 (9.8) 
 Number of deaths 218 485 716 1419 
 CMR/100,000 pys 556 758 972 802 
 LE 18: OATS 48.80 (45.08-55.32) 50.62 (44.75-54.44) 50.93 (45.38-55.05) 50.71 (45.43-54.73) 
 LE 18: Gen. Pop. 65.64 66.56 67.23 66.53 
 Deficit 16.85 15.94 16.30 15.81 
LE 18 = life expectancy at age 18 
OATS = study population (people with a history of opioid agonist therapy) 
CMR = crude mortality rate 
pys = person-years 
Gen. Pop. = general population 
‘Mean age’ is the mean age across all days of follow-up (with age of each participant calculated on each day). ‘Mean age: 
incident’ is the mean age of new participants joining the cohort, at cohort entry. 
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